Zyvox® Annual Appraisal of Potency and Spectrum Program results for 2006:: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries

The Zyvox (R) Annual Appraisal of Potency and Spectrum Program has completed its fifth year of monitoring for emerging resistance to linezolid and other Gram-positive active agents on the continents of Europe, Asia, Australia, and Latin America. In 2006, 4216 Gram-positive isolates from 16 nations were submitted for analysis from 6 organism groups including Staphylococcus aureus (54.0%), coagulase-negative staphylococci (CoNS) (14.6%), enterococci (10.0%), Streptococcus pneumoniae (9.4%), viridans group streptococci (5.0%), and beta-hemolytic streptococci (7.0%). Linezolid retained potent activity against S. aureus MIC50 and MIC90, 2 mu g/mL; 39.8% methicillin resistant) and CoNS (MIC50 and MIC90, I mu g/mL; 74.3% methicillin resistant). Despite endemicity of vancomycin-resistant enterococci (up to 30.0%) in several nations, linezolid inhibited >99% of strains at <= 2 mu g/mL (modal MIC, 1 mu g/mL). Among streptococci, all linezolid MIC values were <= 2 mu g/mL. Rare instances of linezolid-resistance were detected in enterococci (2 isolates, China and Germany) and CoNS (3 isolates, Italy and Brazil); 2 CoNS and 1 Enterococcusfiaecium had documented G2576T mutations. Overall, linezolid remained active against 99.88% of tested strains from this global collection. (C) 2007 Elsevier Inc. All rights reserved.